Business Context and Reporting Period
Company: PharmAthene, Inc. (Note: Request metadata listed "Altimmune, Inc.", but the filing text identifies the registrant as PharmAthene, Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2009
Business Overview: PharmAthene is a biodefense company developing medical countermeasures against biological and chemical weapons. The company has no commercial products and relies on U.S. government contracts and grants for revenue. Key product candidates include SparVax™ (anthrax vaccine), Valortim® (anthrax monoclonal antibody), Protexia® (nerve agent countermeasure), a third-generation anthrax vaccine, and RypVax™ (plague vaccine).
Key Financial Metrics
| Metric | 2009 | 2008 |
|---|---|---|
| Total Revenue | $27.5 million | $32.9 million |
| Net Loss | $(32.3) million | $(36.4) million |
| Research & Development Expenses | $30.2 million | $31.8 million |
| General & Administrative Expenses | $22.4 million | $19.4 million |
| Cash and Cash Equivalents (Year End) | $2.7 million | $19.8 million |
| Short-Term Investments | $3.1 million | $3.2 million |
| Total Debt (Convertible Notes) | $17.4 million (net of discount) | $13.4 million (current) + $0.9 million (long-term) |
| Accumulated Deficit | $(156.3) million | $(123.8) million |
Note: The filing does not provide specific gross margin or operating margin percentages. The company operates at a loss.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased by approximately $5.4 million (16%) from 2008 to 2009. This was primarily driven by a significant drop in revenue from the Protexia® program ($6.9M in 2009 vs. $19.5M in 2008) as the program shifted from pre-clinical development to clinical evaluation and the initial contract phase concluded.
- Debt Restructuring: In July 2009, the company completed a private placement, exchanging $8.8 million of "Old Notes" and issuing $10.5 million in "New Convertible Notes." This resulted in a $4.7 million loss on the early extinguishment of debt.
- Cash Position: Cash and cash equivalents decreased by $17.1 million, largely due to net cash used in operations ($28.1 million) and a $7.0 million payment of deferred consideration to Avecia related to the 2008 acquisition.
- Exit Activities: The company incurred approximately $2.1 million in costs related to transitioning operations and manufacturing from the UK to the U.S.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Guidance
Management believes existing cash resources and contract receivables will fund operations through the end of 2010. However, the company anticipates continued losses and negative cash flow. Future funding is heavily dependent on U.S. government contract awards.
Material Risks and Contingencies
- Contract Protest: In March 2010, a third party filed a bid protest with the GAO challenging a February 2010 contract modification with BARDA for SparVax™ (potential value up to $78 million). Performance under this modification was suspended pending the GAO ruling (expected by June 11, 2010).
- Clinical Hold: A Phase I clinical trial for Valortim® was placed on partial clinical hold by the FDA in August 2009 following two adverse reactions in subjects. BARDA has paused funding negotiations for Valortim® until the hold is lifted.
- Government Contract Performance: In February 2010, NIAID raised concerns regarding performance on the third-generation anthrax vaccine contract, requiring a revised development plan.
- Supplier Risk: The contract manufacturer for the pegylation reagent for Protexia® intends to cease operations, requiring PharmAthene to find an alternative supplier and execute a technology transfer.
- Legal Proceedings: Ongoing litigation with Siga Technologies, Inc. regarding rights to the drug candidate SIGA-246. Discovery closed in February 2010, with summary judgment motions pending.
Key Facts for Investor Verification
- Liquidity Runway: Verify if the company's cash position ($5.8M total liquid assets) is sufficient to cover operations through 2010, especially given the suspension of the $61M SparVax™ contract modification.
- Valortim® Clinical Status: Confirm the resolution of the FDA clinical hold on the Valortim®/ciprofloxacin study and the timeline for resuming BARDA funding negotiations.
- GAO Protest Outcome: Monitor the GAO ruling on the bid protest regarding the SparVax™ contract modification, as a sustained protest could terminate the contract and eliminate a major revenue source.
- Debt Obligations: Review the terms of the $19.3 million New Convertible Notes (maturing July 2011) and the potential dilution from conversion (approx. 7.6 million shares) and warrant exercises.
- Government Funding Dependency: Assess the risk of reduced U.S. government biodefense spending and the impact of the cancelled RFP-BARDA-08-15 on future revenue projections.